Osteoporosis
Özet
Osteoporosis is a disease of the skeleton that thins and weakens the bones. With the increasing age, osteoporosis has become a common health condition. It is characterized by low bone mass and impairment of the microarchitectural construction of the bone tissue, resulting in increased bone breakability and fractures. This definition is an international consensus set at the 1990 World Health Organization Osteoporosis Conference. Osteoporosis is classified in different ways. Among these classifications, the most frequently used classification type in clinical life is classification according to etiology. Our epidemiological information about osteoporosis is insufficient. Because the disease has no witness criteria. Since fractures are the only objective finding of the disease, epidemiological studies have focused on fractures. By identifying the risk factors for osteoporosis and fractures, we can identify individuals who are at high risk and take steps to prevent fractures by modifying risk factors that can be changed.. Many factors can play a role in the pathogenesis of osteoporosis. Throughout life, there is a constant production and destruction of bone. Osteoporosis results from decreased new bone formation or increased bone resorption. Lifetime bone loss is 20% in the men population and 40% in the women population. Turkey is an aging and developing country, and osteoporosis is big health problem. According to the FRAKTURK study, while Turkey still has a relatively low rate of hip fractures compared to other countries in Europe, the incidence of hip fractures appears to have increased significantly in the past 20 years. Knowing the pathogenesis well ensures that the treatment is effective. In the treatment of osteoporosis, the goal is to prevent fractures, increase bone density, and improve the patient's quality of life. We can become healthier societies by preventing osteoporosis, detecting it early and preventing its progression.
Referanslar
Melikoğlu M. Osteoporoz tanımlaması ve sınıflaması. Turkiye Klinikleri J PM&R-Special Topics 2012;5(3):1-5.
Sweet MG, Sweet J, Jeremiah MP, Galazka SS. Diagnosis and treatment of osteoporosis. Am Fam Physician 2009;79(3):193-20 0.
Edwards MH, Jameson K, Denison H, Harvey NC, Sayer AA, Dennison EM, et al. Clinical risk factors, bone density and fall history in the prediction of incident fracture among men and women. Bone 2013;52(2):541-7.
Şen N, Tuncer T. Osteoporoz patofizyolojisi. Türkiye Klinikleri J PM&R-Special Topics 2012;5(3):11-6.
Bonjour JP, Chevalley T, Ferrari S, Rizzoli R. The importance and relevance of peak bone mass in the prevalence of osteoporosis. Salud Publica Mex 2009;51(Suppl 1):5-17.
Wong PK, Christie JJ, Wark JD. The effects of smoking on bone health. Clin Sci (Lond.) 2007;113(5): 233-41.
Türkiye İstatistik Kurumu [internet]. Küresel yetişkin tütün araştırması, 2012 [cited 2015 Jul 9]. Available from: http://www.tuik.gov.tr/PreHa berBultenleri.do?id=13142.
Arasıl T. Osteoporoz epidemiyolojisi ve Türkiye verileri. Türkiye Klinikleri J PM&R-Special Topics 2012;5(3):6-10.
Tuzun S, Eskiyurt N, Akarirmak U, Saridogan M, Senocak M, Johansson H, et al. Incidence of hip fracture and prevalence of osteoporosis in Turkey: the FRACTURK study. Osteoporos Int 2012;23(3):949-55
10.Uğur M. Osteoporozda risk faktörleri. Turkiye Klinikleri J PM&R-Special Topics, 2012;5(3):17-22
Erdem HR. Osteoporozda tanı yöntemleri. Turkiye Klinikleri J PM&R-Special Topics 2012;5(3):34-42.
Civitelli R, Armamento-Villareal R, Napoli N. Bone turnover markers: understanding their value in clinical trials and clinical practice. Osteoporos Int 2009;20(6):843-51.
National Osteoporosis Foundation [Internet]. Clinician’s guide to prevention and treatment of osteoporosis 2010 [cited 2015 Oct 10]. Available from: http://nof.org/files/nof/public/ content/file/344/upload/159.p df
Wheater G, Elshahaly M, Tuck SP, Datta HK, van Laar JM. The clinical utility of bone m arker measurements in osteop orosis. J Transl Med 2013;(11):201.
Tang BM, Eslick GD, Nowson C, Smith C, Bensoussan A. Use of calcium or calcium in combination with vitamin D supplementation to prevent fractures and bone loss in people aged 50 years and older: a meta-analysis. Lancet 2007;370(9588):657-66.
Yamauchi H, Suzuki H, Orimo H. Calcitonin for the treatment of osteoporosis: dosage and dosing interval in Japan. J Bone Miner Metab 2003;21(4):198-204.
Akesson K. New approaches to pharmacological treatment of osteoporosis. Bull World Health Organ 2003;81(9):657-64.
McClung M, Harris ST, Miller PD, Bauer DC, Davison KS, Dian L, et al. Bisphosphonate therapy for osteoporosis: benefits, risks, and drug holiday. Am J Med 2013;126:13-20.
Roelofs AJ, Thompson K, Gordon S, Rogers MJ. Molecular mechanisms of action of bisphosphonates: current status. Clin Cancer Res 2006;12:6222-30.
Xu XL, Gou WL, Wang AY, Wang Y, Guo QY, Lu Q, et al. Basic research and clinical applications of bisphosphonates in bone disease: what have we learned over the last 40 years? J Transl Med 2013;11:303.
National Osteoporosis Foundation. Clinician’s Guide to Prevention and Treatment of Osteoporosis. Washington, DC: National Osteoporosis Foundation, 2013.
Rizzoli R, Adachi JD, Cooper C, Dere W, Devogelaer JP, Diez-Perez A, et al. Management of glucocorticoid-induced osteoporosis. Calcif Tissue Int 2012;91:225-43.
Herrera A, Lobo-Escolar A, Mateo J, Gil J, Ibarz E, Gracia L. Male osteoporosis: A review. World J Orthop 2012;3:223-34.
Lippuner K. The future of osteoporosis treatment - a research update. Swiss Med Wkly 2012;142:13624.
Diab DL, Watts NB. Denosumab in osteoporosis. Expert Opin Drug Saf 2013.
Cummings SR, San Martin J, McClung MR, Siris ES, Eastell R, Reid IR, et al. Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med 2009;361:756-65.
Seeman E, Delmas PD, Hanley DA, Sellmeyer D, Cheung AM, Shane E, et al. Microarchitectural deterioration of cortical and trabecular bone: differing effects of denosumab and alendronate. J Bone Miner Res 2010;25:1886-94.
Bone HG, Chapurlat R, Brandi ML, Brown JP, Czerwinski E, Krieg MA, et al. The effect of three or six years of denosumab exposure in women with postmenopausal osteoporosis: results from the FREEDOM extension. J Clin Endocrinol Metab 2013;98:4483-92.
Grey A, Bolland M. Web of industry, advocacy, and academia in the management of osteoporosis. BMJ 2015;(351):h3170. doi: 10.1136/bmj.h3170.
Eskiyurt N. Osteoporozdan korunma; genel önlemler (kalsiyum, d vitamini ve fiziksel aktivite). Turkiye Klinikleri J PM&R-Special Topics 2012;5(3):98-103.
Das S, Crockett JC. Osteoporosis - a current view of pharmacological prevention and treatment. Drug Des Devel Ther 2013;7:435-48
Hurtel-Lemaire AS, Mentaverri R, Caudrillier A, Cournarie F, Wattel A, Kamel S, et al. The calcium-sensing receptor is involved in strontium ranelate-induced osteoclast apoptosis. New insights into the associated signaling pathways. J Biol Chem 2009;284:575-84.
Cianferotti L, D’Asta F, Brandi ML. A review on strontium ranelate long-term antifracture efficacy in the treatment of postmenopausal osteoporosis. Ther Adv Musculoskelet Dis 2013;5:127-39.
Reginster JY, Kaufman JM, Goemaere S, Devogelaer JP, Benhamou CL, Felsenberg D, et al. Maintenance of antifracture efficacy over 10 years with strontium ranelate in postmenopausal osteoporosis. Osteoporos Int 2012;23:1115-22.
Rizzoli R, Reginster JY. Adverse drug reactions to osteoporosis treatments. Expert Rev Clin Pharmacol 2011;4:593-604.
http://www.ema.europa.eu/ema/index.
Whitaker M, Guo J, Kehoe T, Benson G. Bisphosphonates for osteoporosis--where do we go from here? N Engl J Med 2012;366:2048-51.
Diab DL, Watts NB. Bisphosphonate drug holiday: who, when and how long. Ther Adv Musculoskelet Dis 2013;5:107-11.
Sindel D. Osteoporozda rehabilitasyon. Osteoporoz Kitabı. İstanbul: Epsilon Matbaası; 2002. s.122-34.
Oral A, Küçükdeveci AA, Varela E, Ilieva EM, Valero R, Berteanu M, et al. Osteoporosis. The role of physical and rehabilitation medicine physicians. The European perspective based on the best evidence. A paper by the UEMS-PRM Section Professional Practice Committee. Eur J Phys Rehabil Med 2013;49:565-77.
Howe TE, Shea B, Dawson LJ, Downie F, Murray A, Ross C, et al. Exercise for preventing and treating osteoporosis in postmenopausal women. Cochrane Database Syst Rev 2011;CD000333.
Slatkovska L, Alibhai SM, Beyene J, Cheung AM. Effect of wholebody vibration on BMD: a systematic review and meta-analysis. Osteoporos Int 2010;21:1969-80.
Lau RW, Liao LR, Yu F, Teo T, Chung RC, Pang MY. The effects of whole body vibration therapy on bone mineral density and leg muscle strength in older adults: a systematic review and meta-analysis. Clin Rehabil 2011;25:975-88.
Sindel D, Dilşen G, Kubat A. Postmenopozal osteoporozda rehabilitasyon açısından yaşam kalitesi sonuçları. Romatol Tıp Rehab 1995;6:144-8.
